View Cart  

FDA Advisory Panel Narrowly Favors Approval of Genzyme HoFH Drug

A A
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9–6 Thursday to recommend approval of Genzyme and Isis Pharmaceuticals’ homozygous familial hypercholesterolemia (HoFH) drug Kynamro.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00